SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty - Cassava Sciences ( NASDAQ:SAVA )

3 weeks ago

Alzheimer's drug developer Cassava Sciences Inc SAVA, its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, ...

Ticker	Sentiment	Impact
SAVA	Neutral	36 %